These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

742 related articles for article (PubMed ID: 34856198)

  • 1. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
    Lasa JS; Olivera PA; Danese S; Peyrin-Biroulet L
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):161-170. PubMed ID: 34856198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative of the effectiveness and safety of biological agents, small molecule drugs, and microbiome therapies in ulcerative colitis: Systematic review and network meta-analysis.
    Gao J; Nie R; Chen Y; Yang W; Ren Q
    Medicine (Baltimore); 2023 Oct; 102(43):e35689. PubMed ID: 37904440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis.
    Chu X; Biao Y; Liu C; Zhang Y; Liu C; Ma JZ; Guo Y; Gu Y
    BMC Gastroenterol; 2023 Oct; 23(1):346. PubMed ID: 37803294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
    Singh S; Fumery M; Sandborn WJ; Murad MH
    Aliment Pharmacol Ther; 2018 Jan; 47(2):162-175. PubMed ID: 29205406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.
    Singh S; Murad MH; Fumery M; Dulai PS; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2179-2191.e6. PubMed ID: 31945470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
    Bonovas S; Lytras T; Nikolopoulos G; Peyrin-Biroulet L; Danese S
    Aliment Pharmacol Ther; 2018 Feb; 47(4):454-465. PubMed ID: 29205421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of biological interventions for ulcerative colitis on health-related quality of life.
    LeBlanc K; Mosli MH; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis.
    Trigo-Vicente C; Gimeno-Ballester V; García-López S; López-Del Val A
    Int J Clin Pharm; 2018 Dec; 40(6):1411-1419. PubMed ID: 30478492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
    Moćko P; Kawalec P; Pilc A
    Pharmacotherapy; 2016 Aug; 36(8):870-9. PubMed ID: 27312826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
    Attauabi M; Dahl EK; Burisch J; Gubatan J; Nielsen OH; Seidelin JB
    EClinicalMedicine; 2023 Mar; 57():101866. PubMed ID: 36864986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Efficacy of Biologics and Small Molecule Therapies in Improving Patient-Reported Outcomes in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
    Shehab M; Hassan A; Alrashed F; Abbas A; Ma C; Narula N; Jairath V; Singh S; Bessissow T
    Inflamm Bowel Dis; 2024 Aug; ():. PubMed ID: 39137239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
    Nguyen NH; Fumery M; Dulai PS; Prokop LJ; Sandborn WJ; Murad MH; Singh S
    Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):742-753. PubMed ID: 30122356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etrolizumab for induction of remission in ulcerative colitis.
    Rosenfeld G; Parker CE; MacDonald JK; Bressler B
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011661. PubMed ID: 26630451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparative efficacy and safety of biologics and small molecules for treating patients with ulcerative colitis in Portugal: a systematic literature review and network meta-analysis.
    Sanchez Gonzalez Y; Prata R; Alves D
    Eur Rev Med Pharmacol Sci; 2023 Jul; 27(14):6744-6759. PubMed ID: 37522686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease.
    Singh S; Fumery M; Sandborn WJ; Murad MH
    Aliment Pharmacol Ther; 2018 Aug; 48(4):394-409. PubMed ID: 29920733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis.
    Lu X; Zhou ZY; Xin Y; Wang MJ; Gray E; Jairath V; Lindsay JO
    Inflamm Bowel Dis; 2024 Jan; 30(1):64-77. PubMed ID: 36946138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An indirect comparison of efficacy including histologic assessment and safety in biologic therapy in ulcerative colitis: Systemic review and network meta-analysis.
    Chae K; Seo YS; Yu YM; Chang MJ; Choi J
    PLoS One; 2023; 18(11):e0293655. PubMed ID: 37917756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.
    Jairath V; Zou GY; Parker CE; MacDonald JK; AlAmeel T; Al Beshir M; Almadi MA; Al-Taweel T; Atkinson NS; Biswas S; Chapman T; Dulai PS; Glaire MA; Hoekman DR; Koutsoumpas A; Minas E; Mosli MH; Samaan M; Khanna R; Travis S; D'Haens G; Sandborn WJ; Feagan BG
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011572. PubMed ID: 28886205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis.
    Rokkas T; Gisbert JP; Ekmektzoglou K; Dassopoulos T; Niv Y; O'Morain C
    Eur J Gastroenterol Hepatol; 2024 May; 36(5):520-533. PubMed ID: 38477863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.